Beaver-Visitec International, Inc.

Dr. Robert Bastian, the first to successfully define, treat and resolve R-CPD, reaches this milestone during National Digestive Diseases Awareness Month, May 2024. DOWNERS GROVE, Ill., May 1, 2024 /PRNewswire/ -- Dr. Robert Bastian, renowned laryngologist and founder of Bastian Voice Institute (BVI), achieves a major milestone on May 1, 2024. Kicking off National Digestive Diseases Awareness Month, Dr. Bastian will treat his 1,000th patient with the diagnosis of R-CPD (Retrograde Cricopharyngeus Dysfunction), a digestive disorder that he first described as a detailed syndrome in 2015, when he also became the first to successfully treat and resolve this condition. R-CPD occurs when the upper esophageal sphincter will not relax in order to release intestinal gas and is the formal name for a condition comprised by a collection of symptoms all tied to an inability to burp (or burp sufficiently). Continue Reading Robert W. Bastian, M.D. "The significance of treating my 1,000th R-CPD patient during National Digestive Diseases Awareness Month couldn't be more fitting," states Bastian. "Because many of the primary symptoms are generally GI-related—including the inability to belch, gurgling noises, chest/abdominal pressure, bloating, and flatulence—prior to coming to us, patients have typically endured testing that has often been inconclusive. These patients have also many times been treated for the individual symptoms, rather than the underlying cause, resulting in little to no relief. Bringing awareness to this specific condition, and shedding light on the readily available, proven treatment is of paramount importance to me." Until Dr. Bastian codified R-CPD as a condition, it was unknown as a specific diagnosis in the medical community. Dr. Bastian and partners, Dr. Brent Richardson and Dr. Rebecca Hoesli, together have treated over 1,700 patients with R-CPD at Bastian Voice Institute (BVI). Most undergo a brief outpatient procedure to inject botulinum toxin into the esophageal sphincter, and a small subset instead opts for an in-office procedure using electromyographic guidance. "Patients routinely experience dramatic relief of their symptoms. Typically, a single Botox injection serves as 'training wheels,' allowing the system to reset, and the person may never lose his or her ability to belch again," Bastian states. Bastian is also quick to note that while the total caseload at BVI has reached people from 50 states and 26 countries, this treatment is becoming more widely available, and he himself is actively involved in bringing it to colleagues in the gastrointestinal and other medical specialties. "I specifically created an extensive online resource, , where we provide as a public service information designed to help both patients and their physicians understand R-CPD and help them find and provide help, wherever they are located," Bastian concludes. To learn more about R-CPD and Dr. Bastian's work visit . About BVI Bastian Voice Institute (BVI) was founded in 2003 by Robert W. Bastian, M.D. and provides the highest quality medical, surgical and behavioral care and consideration for persons with voice, swallowing and airway disorders. BVI's primary concern is patient care, supported by ongoing educational activities and research projects. Following a successful 20-year career in academic medicine, first at Washington University in St. Louis and then at Loyola University in Chicago where he rose to the rank of Professor, Dr. Bastian founded BVI, inspired by his vision of a unique primary-through-tertiary-care specialty practice. In 2015, Dr. Bastian was the first to fully understand, codify and successfully treat R-CPD (Retrograde Cricopharyngeus Dysfunction). As part of Dr. Bastian's commitment to education and accessibility to care, he created and hosts the informational website , providing a valuable resource for clinicians and patients alike. For more information visit . SOURCE Bastian Voice Institute

DUBLIN--( BUSINESS WIRE )--The "Surgical Sealants, Adhesives and Hemostats Global Market - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. SAH global market is expected to grow at mid-single digit CAGR from 2022 to 2029 to reach $4,366.0 million by 2029 The SAH global market is mainly segmented based on products, applications, end-users, and based on geography. The product market is segmented into sealant, adhesive and hemostat. Among these, the hemostat accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. The sealants are further segmented based on their origin into natural and synthetic sealants. The synthetic sealant accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029. The natural sealants are further sub-segmented based on composition into fibrin and albumin sealants. Among them, fibrin accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029. The synthetic sealants are further segmented based on composition into cyanoacrylate, hydrogels, and others. Among them, hydrogels accounted for the largest revenue in 2022 and are expected to grow at mid-single digit CAGR from 2022 to 2029. The adhesive market is segmented into natural and synthetic adhesives, among them; synthetic adhesives accounted for the largest revenue in 2022 and are expected to grow at low-single digit CAGR from 2022 to 2029. The natural adhesives are further sub-segmented based on composition into fibrin and albumin, among them, fibrin adhesive accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029. The synthetic adhesives are further segmented based on composition into cyanoacrylate and polyurethane. The cyanoacrylate adhesive accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029. Hemostats are classified based on function into mechanical hemostats, active hemostats, flowable hemostats, and fibrin sealants hemostats, among them, the mechanical hemostats accounted for the largest revenue in 2022 and are expected to grow at mid-single digit CAGR from 2022 to 2029. Fibrin sealant hemostat is the fastest growing segment at high-single digit strong CAGR from 2022 to 2029 because it is unique, powerful and effective for localized and diffused bleeding during surgical procedures. The application market is segmented into Cardiovascular surgery, General Surgery, Orthopedic surgery, Urology, Pulmonology, Neurosurgery, Gynecology, Cosmetic surgery and Others. The general surgery segment accounted for the largest revenue in 2022 and is expected to grow at low-single digit CAGR from 2022 to 2029, because of high demand for various surgical procedures. Cosmetic surgery is the fastest growing segment at high-single digit CAGR, because of the advancements in treatment regimes available and better cosmetic outcomes. The end-users market is segmented into hospitals, ambulatory surgical centers, and others. The hospital segment accounted for the largest share in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029, due to an increase in the aging population, increase in surgical procedural volumes, and better patient care services with advanced facilities. Factors Influencing Market Drivers and Opportunities Increasing Demand for Surgical Procedures Boosts Sah Market Growth the Emergence of Technically Advanced Products Increasing Geriatric Population Acquisition to Open An Array of Opportunities for the Market to Flourish Acceptance of Sah and Market Expansion in Emerging Nations Restraints and Threats Pitfalls in the Usage of Sah Expensive Sah Impeding Effective Penetration in Low and Middle-Income Countries Unfavorable Reimbursement Policies in Developing Nations Stringent Regulatory Guidelines Availability of Alternative Products Major Companies Advanced Medical Solutions Artivion Baxter International, Inc B.Braun Melsungen AG Becton, Dickinson and Company (C.R.Bard Inc.) Corza Medical Integra Lifescience Johnson & Johnson (Ethicon) Medtronic, plc Teleflex Regulatory Affairs International Organization for Standardization Iso 9001: 2015 Quality Management System Iso 14644-1 Cleanroom Standards Iso 13485 Medical Devices Iso 10993 Biological Evaluation of Medical Devices Astm International Standards U.S. Canada Europe Japan China India Technological Advancements Bioglue Bioinspired Glue from Barnacles Snake-Derived Super Glue Alga Mimetic Technology a Polymer Patch for the Abdominal Cavity Clinical Trials Scope of the Market Surgical Sealants, Adhesives and Hemostats Global Market, Based on Product Sealants Natural Sealants Fibrin Natural Sealants Albumin Natural Sealants Synthetic Sealants Cyanoacrylate Hydrogels Others Adhesives Natural Adhesives Fibrin Natural Adhesives Albumin Natural Adhesives Synthetic Adhesives Cyanoacrylate Polyurethane Hemostats Mechanical Hemostats Active Hemostats Flowable Hemostats Fibrin Sealant Hemostats Surgical Sealants, Adhesives and Hemostats Global Market, Based on Application Cardiovascular Surgery General Surgery Orthopedic Surgery Urology Pulmonology Neurosurgery Gynecology Cosmetic Surgery Others Surgical Sealants, Adhesives and Hemostats Global Market, Based on End-Users Hospitals Ambulatory Surgical Centers Others Companies Mentioned Adhezion Biomedical, LLC Advanced Medical Solutions Group plc (Selantis) Aegis-Lifesciences Artivion (Cryolife) Axio Bioscience B.Braun Melsungen AG Baxter International, Inc. Becton Dickinson and Company (Tissumed) Beaver Visitec International Betatech Medical Biocer Entwicklungs-Gmbh Biom'Up Boz Medical Chemence Medical, Inc. Corza Medical CSL Behring Dalim Tissen Dsi Ltd Equimedical Gatt Tech Gelita Medical Gem Srl Glustitich, Inc. Green Cross Biopharma Grena Grunenthal GmbH (Adhesys Medical Gmbh) H.B. Fuller Hager & Werken GmbH & Co. Kg Haulan Bioengineering Co Ltd Healthium Hemarus Therapeutics Hemostatis Ibc Pharmaceuticals, Ltd. Integra Lifesciences Holding Corporation Johnson & Johnson (Ethicon) Katsan Medical Devices Medtronic Meril Life Sciences Pvt. Ltd Ocular Therapeutix, Inc. Optmed, Inc. Peter Surgical Pfizer Reliance Lifescience Samyang Holdings Corporation Shanghai Raas Starsil Hemostat Stryker Symatese Teleflex Terumo Corporation Theracion Biomedical Tissium (Gecko Medical) Tricol Biomedical Vivostat A/S Wortham Laboratories Inc Zhejiang Perfectseal For more information about this report visit https://www.researchandmarkets.com/r/u7svcu

DUBLIN--( BUSINESS WIRE )--The "Vitreo Retinal Surgery Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering. The report enables you to: Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Vitreo Retinal Surgery Devices under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Scope Extensive coverage of the Vitreo Retinal Surgery Devices under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Vitreo Retinal Surgery Devices and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment/industry Key Topics Covered: 1 Table of Contents 2 Introduction 3 Products under Development 3.1 Vitreo Retinal Surgery Devices - Pipeline Products by Stage of Development 3.2 Vitreo Retinal Surgery Devices - Pipeline Products by Territory 3.3 Vitreo Retinal Surgery Devices - Pipeline Products by Regulatory Path 3.4 Vitreo Retinal Surgery Devices - Pipeline Products by Estimated Approval Date 3.5 Vitreo Retinal Surgery Devices - Ongoing Clinical Trials 4 Vitreo Retinal Surgery Devices - Pipeline Products under Development by Companies 4.1 Vitreo Retinal Surgery Devices Companies - Pipeline Products by Stage of Development 4.2 Vitreo Retinal Surgery Devices - Pipeline Products by Stage of Development 5 Vitreo Retinal Surgery Devices Companies and Product Overview 5.1 ABVC BioPharma Inc Company Overview 5.2 AcuSurgical Company Overview 5.3 Alcon Inc Company Overview 5.4 Bausch & Lomb Inc Company Overview 5.5 Beaver-Visitec International Inc Company Overview 5.6 Boston College Company Overview 5.7 Cambridge Polymer Group Inc Company Overview 5.8 Carnegie Mellon University Company Overview 5.9 Duke University Company Overview 5.10 Dutch Ophthalmic Research Center International BV Company Overview 5.11 Johns Hopkins University Company Overview 5.12 King's College London Company Overview 5.13 Medisse BV (Inactive) Company Overview 5.14 RetinaSense Company Overview 5.15 Synergetics USA, Inc. (Inactive) Company Overview 5.16 The Chinese University of Hong Kong Company Overview 5.17 University of Kansas Company Overview 5.18 University of Minnesota Company Overview 6 Vitreo Retinal Surgery Devices- Recent Developments 7 Appendix For more information about this report visit https://www.researchandmarkets.com/r/zd122m Source: GlobalData